Diversity screening versus focussed screening in drug discovery.
Which strategy is best for hit identification? Making the right choices in the capital-intensive world of modern drug discovery can make the difference between success and expensive failure. Keeping an open mind to all the options is essential. Two well-established strategies are diversity-based and focussed screening. This review will provide contrasting viewpoints highlighting the strengths and deficiencies of each approach, as well as some insights into why both strategies are likely to have a place in the research armoury of a successful drug company.
Valler
MJ
Molecular Discovery Department, GlaxoWellcome R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, UK SG1 2NY.
Green
D